ATE204260T1 - 4,6-dianilino-pyrimidin derivate, deren herstellung und deren verwendung als tyrosin- kinase inhibitoren - Google Patents

4,6-dianilino-pyrimidin derivate, deren herstellung und deren verwendung als tyrosin- kinase inhibitoren

Info

Publication number: ATE204260T1
Authority: AT; Austria
Prior art keywords: alkyl; pct; substituted; amino; preparation
Prior art date: 1993-12-09

Application number

AT95902854T

Other languages

English (en)

Inventor

Andrew Peter Thomas

Park Alderley

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-09

Filing date

1994-12-05

Publication date

2001-09-15

1994-12-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-09-15 Application granted granted Critical

2001-09-15 Publication of ATE204260T1 publication Critical patent/ATE204260T1/de

Links

FGDGJJNJEUYMFK-UHFFFAOYSA-N 4-n,6-n-diphenylpyrimidine-4,6-diamine Chemical class C=1C(NC=2C=CC=CC=2)=NC=NC=1NC1=CC=CC=C1 FGDGJJNJEUYMFK-UHFFFAOYSA-N 0.000 title 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
125000004414 alkyl thio group Chemical group 0.000 abstract 2
125000005530 alkylenedioxy group Chemical group 0.000 abstract 2
-1 cyano, carboxy Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
125000004423 acyloxy group Chemical group 0.000 abstract 1
125000005236 alkanoylamino group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1
102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT95902854T 1993-12-09 1994-12-05 4,6-dianilino-pyrimidin derivate, deren herstellung und deren verwendung als tyrosin- kinase inhibitoren ATE204260T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB939325217A GB9325217D0 (en)	1993-12-09	1993-12-09	Pyrimidine derivatives
PCT/GB1994/002659 WO1995015952A1 (en)	1993-12-09	1994-12-05	4,6-dianilino-pyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE204260T1 true ATE204260T1 (de)	2001-09-15

Family

ID=10746350

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95902854T ATE204260T1 (de)	1993-12-09	1994-12-05	4,6-dianilino-pyrimidin derivate, deren herstellung und deren verwendung als tyrosin- kinase inhibitoren

Country Status (13)

Country	Link
US (1)	US5880130A (de)
EP (1)	EP0733045B1 (de)
JP (1)	JP3583783B2 (de)
AT (1)	ATE204260T1 (de)
AU (1)	AU1194895A (de)
DE (1)	DE69427991T2 (de)
DK (1)	DK0733045T3 (de)
ES (1)	ES2163492T3 (de)
GB (2)	GB9325217D0 (de)
IL (1)	IL111896A0 (de)
PT (1)	PT733045E (de)
WO (1)	WO1995015952A1 (de)
ZA (1)	ZA949546B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW321649B (de) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
JPH11507329A (ja) *	1995-04-27	1999-06-29	ゼネカリミテッド	キナゾリン誘導体
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
DE69720965T2 (de)	1996-02-13	2004-02-05	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
GB9603097D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
WO1998033798A2 (en) *	1997-02-05	1998-08-06	Warner Lambert Company	Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
KR100643419B1 (ko)	1998-03-27	2006-11-10	얀센 파마슈티카 엔.브이.	Ｈｉｖ를 억제하는 피리미딘 유도체
US6632820B1 (en)	1998-08-29	2003-10-14	Astrazeneca Ab	Pyrimidine compounds
ATE342892T1 (de)	1998-08-29	2006-11-15	Astrazeneca Ab	Pyrimidine verbindungen
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
GB9907658D0 (en)	1999-04-06	1999-05-26	Zeneca Ltd	Chemical compounds
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
TR200200763T2 (tr)	1999-09-24	2003-09-22	Janssen Pharmaceutica N.V.	Antiviral bileşimler
DE19945982A1 (de) *	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
KR100881105B1 (ko)	1999-11-05	2009-02-02	아스트라제네카 아베	Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004886D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0007371D0 (en)	2000-03-28	2000-05-17	Astrazeneca Uk Ltd	Chemical compounds
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
GB0021726D0 (en)	2000-09-05	2000-10-18	Astrazeneca Ab	Chemical compounds
CN100525768C (zh)	2000-10-23	2009-08-12	史密丝克莱恩比彻姆公司	新化合物
GB0113041D0 (en)	2001-05-30	2001-07-18	Astrazeneca Ab	Chemical compounds
KR101031720B1 (ko) *	2001-11-28	2011-04-29	비티지 인터내셔널 리미티드	질소함유 헤테로아릴 화합물을 함유하는 알츠하이머병의예방약 또는 치료약 또는 아밀로이드 단백질 섬유화억제제
MXPA04005939A (es)	2002-01-22	2005-01-25	Warner Lambert Co	2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US7442697B2 (en)	2002-03-09	2008-10-28	Astrazeneca Ab	4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205690D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0205688D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0205693D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
KR20040103972A (ko)	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
US20050014753A1 (en) *	2003-04-04	2005-01-20	Irm Llc	Novel compounds and compositions as protein kinase inhibitors
GB0311276D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
GB0311274D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
TW200528101A (en)	2004-02-03	2005-09-01	Astrazeneca Ab	Chemical compounds
US7423042B2 (en)	2005-03-25	2008-09-09	Glaxo Group Limited	Compounds
PE20061193A1 (es)	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
MY145343A (en)	2005-03-25	2012-01-31	Glaxo Group Ltd	Novel compounds
US20080096905A1 (en)	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
AR056556A1 (es)	2005-09-30	2007-10-10	Astrazeneca Ab	Imidazo(1,2-a)piridina con actividad antiproliferacion celular
JP2009514876A (ja) *	2005-11-03	2009-04-09	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼのための化合物および組成物
US20070231298A1 (en) *	2006-03-31	2007-10-04	Cell Genesys, Inc.	Cytokine-expressing cancer immunotherapy combinations
EP2136635A4 (de) *	2007-03-20	2011-07-27	Glaxosmithkline Llc	Chemische verbindungen
EA200901133A1 (ru) *	2007-03-20	2010-04-30	Смитклайн Бичем Корпорейшн	Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
US7989465B2 (en)	2007-10-19	2011-08-02	Avila Therapeutics, Inc.	4,6-disubstituted pyrimidines useful as kinase inhibitors
TWI552752B (zh) *	2007-10-19	2016-10-11	賽基艾維洛米斯研究股份有限公司	雜芳基化合物及其用途
CA2903813C (en)	2013-03-15	2023-08-29	Epizyme, Inc.	Carm1 inhibitors and uses thereof
WO2014144455A1 (en)	2013-03-15	2014-09-18	Epizyme, Inc.	1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
US9346802B2 (en)	2013-03-15	2016-05-24	Epizyme, Inc.	CARM1 inhibitors and uses thereof
CN104844526B (zh) *	2015-04-16	2018-08-31	温州医科大学	一种4,6-嘧啶二胺类化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR80171B (en) *	1983-08-29	1985-01-02	Ciba Geigy Ag	N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use
DE3644799A1 (de) *	1986-06-04	1987-12-10	Hoechst Ag	Neue pyrimidin-derivate, deren herstellung und verwendung
SG64322A1 (en) *	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
AU653024B2 (en) *	1991-05-30	1994-09-15	Novartis Ag	Substituted diaminophthalimides and analogues
NZ243082A (en) *	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5213453A (en) *	1991-06-28	1993-05-25	Tapmatic Corporation	Cooling systems in tapping attachments suitable for high pressure applications
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
TW225528B (de) *	1992-04-03	1994-06-21	Ciba Geigy Ag
US5283274A (en) *	1992-06-19	1994-02-01	Uniroyal Chemical Company, Inc.	Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
IL106324A (en) *	1992-07-17	1998-09-24	Shell Int Research	Transformed pyrimidine compounds, their preparation and use as pesticides
US5728704A (en) *	1992-09-28	1998-03-17	Pfizer Inc.	Substituted pyridmidines for control of diabetic complications
GB9323290D0 (en) *	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314893D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
DK0640599T3 (da) *	1993-08-26	1998-09-28	Ono Pharmaceutical Co	4-Aminopyrimidin-derivater

1993
- 1993-12-09 GB GB939325217A patent/GB9325217D0/en active Pending
1994
- 1994-11-28 GB GB9423966A patent/GB9423966D0/en active Pending
- 1994-11-30 ZA ZA949546A patent/ZA949546B/xx unknown
- 1994-12-05 AT AT95902854T patent/ATE204260T1/de not_active IP Right Cessation
- 1994-12-05 DE DE69427991T patent/DE69427991T2/de not_active Expired - Fee Related
- 1994-12-05 EP EP95902854A patent/EP0733045B1/de not_active Expired - Lifetime
- 1994-12-05 WO PCT/GB1994/002659 patent/WO1995015952A1/en not_active Ceased
- 1994-12-05 DK DK95902854T patent/DK0733045T3/da active
- 1994-12-05 AU AU11948/95A patent/AU1194895A/en not_active Abandoned
- 1994-12-05 ES ES95902854T patent/ES2163492T3/es not_active Expired - Lifetime
- 1994-12-05 JP JP51603195A patent/JP3583783B2/ja not_active Expired - Fee Related
- 1994-12-05 US US08/663,200 patent/US5880130A/en not_active Expired - Fee Related
- 1994-12-05 PT PT95902854T patent/PT733045E/pt unknown
- 1994-12-06 IL IL11189694A patent/IL111896A0/xx unknown

Also Published As

Publication number	Publication date
IL111896A0 (en)	1995-03-15
EP0733045A1 (de)	1996-09-25
WO1995015952A1 (en)	1995-06-15
DK0733045T3 (da)	2001-11-12
ES2163492T3 (es)	2002-02-01
GB9423966D0 (en)	1995-01-11
JP3583783B2 (ja)	2004-11-04
GB9325217D0 (en)	1994-02-09
PT733045E (pt)	2002-02-28
ZA949546B (en)	1995-06-23
US5880130A (en)	1999-03-09
JPH09506363A (ja)	1997-06-24
EP0733045B1 (de)	2001-08-16
DE69427991T2 (de)	2002-04-11
AU1194895A (en)	1995-06-27
DE69427991D1 (de)	2001-09-20

Legal Events

Date	Code	Title	Description
2002-01-15	UEP	Publication of translation of european patent specification
2010-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE204260T1 (de)	2001-09-15	4,6-dianilino-pyrimidin derivate, deren herstellung und deren verwendung als tyrosin- kinase inhibitoren
TW283146B (de)	1996-08-11
MY114425A (en)	2002-10-31	Quinazoline derivatives
TW270117B (en)	1996-02-11	Quinazoline derivatives
DE69216158D1 (de)	1997-02-06	Chinazolinderivate enthaltende therapeutische Zusammensetzungen
IT1277392B1 (it)	1997-11-10	Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
MX9708177A (es)	1998-01-31	Derivados de quinazolina.
MY140507A (en)	2009-12-31	Quinazoline derivatives, pharmaceutical compositions containing them, processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect